SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY FLASH H impact

SMMT: Ivonescimab Approved in China

SMMT's Ivonescimab is approved in China for first-line treatment of squamous non-small cell lung cancer

SMMT

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.